Efemoral Medical

Executive Summary

Efemoral Medical is an early-stage medical technology company developing durable, minimally invasive treatments for peripheral artery disease (PAD), a condition affecting over 200 million people worldwide. Founded in 2015 and headquartered in San Jose, California, the company aims to address the significant unmet need for effective PAD therapies that reduce recurrent interventions and improve patient quality of life. Its proprietary platform focuses on delivering long-lasting outcomes through a novel endovascular approach, differentiating from existing drug-coated balloons and stents that have limitations in durability and safety. While still in preclinical or early clinical stages, Efemoral Medical's technology has the potential to capture a meaningful share of the multi-billion-dollar PAD market if successful.

Upcoming Catalysts (preview)

• TBDInitiation of First-in-Human Clinical Trial70% success
• TBDFDA Breakthrough Device Designation60% success
• TBDSeries A Financing Round Closing80% success